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Abstract 
Biphosphonate-associated maxillary bone osteonecrosis (BPMO) is a complication related to nitrogen-containing 
biphosphonate therapy. This adverse effect occasionally appears in patients who are administered biphosphonates 
through intravenous infusion for the treatment of cancer involving bone metastases. It can also present, in a lesser 
degree, in patients who take these drugs orally for the treatment of osteoporosis. Lately, there has been an increase 
in the number of cases of osteopenia and osteoporosis due to the increasing life expectancy of the world’s popula-
tion. In our country, a risk group composed mainly of older women who have been diagnosed with osteopenia or 
osteoporosis, and submitted to the continuous action of oral biphosphonates, is emerging. In this paper we present 
18 cases of BPMO associated to the use of oral biphosphonates, diagnosed and treated in the Department of Stoma-
tology of the School or Dentistry at Universidad Nacional de Rosario, Argentina. A protocol was designed in which 
the following information was recorded: age and sex of the patients, the original disease which led to therapy with 
oral biphosphonates, the drugs used and the period in which those drugs were administered, the clinical features 
and location of the lesions, together with triggering factors.
Key words: Maxillary osteonecrosis, mandibular osteonecrosis, oral biphosphonates, alendronate, ibandronate. 
doi:10.4317/jced.51694
http://dx.doi.org/10.4317/jced.51694
Introduction
BPMO often appears, with one or several breaks in con-
tinuity, in the alveolar process mucosa, with exposure of 
a necrotic maxillary or mandibular bone which shows 
no tendency to healing. This disease can present sponta-
neously, or after a prosthetic-related trauma, minor den-
tal surgery such as dental extraction or dental implant, 
gingivectomy, etc. There is no scarring of the wound for 
a minimum of 6 to 8 weeks in patients not undergoing 
radiation therapy who are being or have been administe-
red intravenous or oral biphosphonates for long periods. 
The risk of this side effect is related to the cumulated 
dosage, the administration route, and the period in which 
biphosphonates have been administered. Specific risk 
factors have been detected: the intravenous administra-
tion route, the potency of the particular biphosphona-
te, the presence of periodontal disease, the presence of 
diabetes, and the concomitant treatment with systemic 
corticosteroids. Oral biphosphonate-associated BPMO’s 
incidence is very low, between 0.01 and 0.04%. The 
López-D’alessandro E, Mardenlli F, Paz M, Escovich L. Oral bisphosphonate-
associated osteonecrosis of maxillary bone. A review of 18 cases. J Clin Exp 
Dent. 2014;6(5):e530-4.
http://www.medicinaoral.com/odo/volumenes/v6i5/jcedv6i5p530.pdf
Article Number: 51694                http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System
J Clin Exp Dent. 2014;6(5):e530-4.                                                                                                                                                                    Oral bisphosphonate associated osteonecrosis
e531
risk of new cases arising varies between 1/100,000 and 
1/10,000 per year of therapy. These values appear to be 
increasing, especially in patients with osteoarticular pa-
thologies like arthritis, osteopenia, and osteoporosis who 
are being treated with oral biphosphonates (1-10).
Material and Methods 
Eighteen cases of patients with oral biphosphonate-as-
sociated BPMO (taking alendronate or ibandronate) for 
the prophylaxis or treatment of osteopenia or osteoporo-
sis were included in this study after the signature of the 
corresponding informed consent. They were diagnosed 
and treated in the Department of Stomatology, School of 
Dentistry, at Universidad Nacional de Rosario, Argenti-
na, between 2009 and 2013. Cases of BPMO in patients 
who were administered intravenous biphosphonates for 
the treatment of cancer or other osseous pathologies were 
excluded from the study. Patients with diabetes, patients 
receiving concomitant therapy with systemic corticoste-
roids, and those who decided to not give their consent to 
participate were also excluded. A data collection protocol 
was designed, in which the following information was 
registered: age and sex of the patients, clinical findings 
and location of the lesions, type of drugs used, the dosa-
ge and interval between doses, the administration routes 
and the period in which the drugs were administered, the 
original disease which led to the use of biphosphonates, 
and the presence of triggering factors. This study was 
approved by our institution’s bioethics committee.
DRUG USED PERIOD OF 
ADMINISTRATION
MAXILLARY 
LESION 
MANDIBULAR 
LESION
ORIGINAL 
DISEASE
Alendronate, 70mg/
week
4 years - yes osteoporosis
Alendronate, 70mg/
week
10 years - yes osteoporosis
Alendronate, 70mg/
week
7 years yes yes osteopenia
Alendronate, 70mg/
week
3.5 years yes - osteoporosis
Alendronate, 70mg/
week
3 years - yes osteoporosis
Alendronate, 70mg/
week
4 years yes - osteopenia
Alendronate, 70mg/
week
3 years - yes osteoporosis
Alendronate, 70mg/
week
2 years yes - osteoporosis
Alendronate, 70mg/
week
3.5 years yes - osteoporosis
Table 1. BPMO cases associated with the use of alendronate.
Results
The median age of the patients studied was 68 years 
(65-85). Sex distribution showed that only one of the 
patients with BPMO was male, while the remaining 17 
cases developed in female patients. The presence of tri-
ggering factors was confirmed in 44.4% of the patients, 
who associated the onset of the disease with a specific 
situation; 5 patients had dental extractions, 2 had pros-
thetic-related trauma, and 1 had undergone dental im-
plants; none of the remaining 10 patients associated any 
particular factor with the onset of the disease.  As for the 
type of drug used, it was determined that 50% of the ca-
ses were receiving only alendronate at a dose of 70 mg/
week, orally (Table 1).
On the other hand, 44.4% of the patients received only 
150 mg/month of oral ibandronate (Table 2).
It could also be established that only one patient (5.6%) 
received both alendronate and ibandronate concomi-
tantly for 2 years (Table 3).
The period of use of biphosphonates prior to the appea-
rance of BPMO was established, in average, as 4.11 
years; this being the period of administration before the 
appearance of the condition. As for the original disease 
which required the administration of biphosphonates, 
it was determined that 77.8% of the patients had been 
diagnosed with osteoporosis, and the remaining 22.2% 
had osteopenia. As regards the clinical features of the 
lesions, most of them were areas of exposed necrotic 
bone of less than 2 cm, with little bleeding and slightly 
J Clin Exp Dent. 2014;6(5):e530-4.                                                                                                                                                                    Oral bisphosphonate associated osteonecrosis
e532
DRUG USED PERIOD OF 
ADMINISTRATION
MAXILLARY 
LESION 
MANDIBULAR 
LESION
ORIGINAL 
DISEASE
Ibandronate, 150mg/
month
3 years - yes osteoporosis
Ibandronate, 150mg/
month
4 years - yes osteoporosis
Ibandronate, 150mg/
month
3 years - yes osteoporosis
Ibandronate, 150mg/
month
3 years yes - osteopenia
Ibandronate, 150mg/
month
4 years yes - osteopenia
Ibandronate, 150mg/
month
7 years yes - osteoporosis
Ibandronate, 150mg/
month
5 years yes - osteoporosis
Ibandronate, 150mg/
month
3 years - yes osteoporosis
Table 2. BPMO cases associated with the use of ibandronate.
Table 3. BPMO cases associated with the concomitant use of alendronate and ibandronate.
DRUG USED PERIOD OF 
ADMINISTRATION
MAXILLARY 
LESION 
MANDIBULAR 
LESION
ORIGINAL 
DISEASE
Alendronate 70mg/
week+ Ibandronate 
150mg/month
2 years yes - osteoporosis
painful; some were also secondarily infected. (Figs. 1,2) 
In 94.4% of the cases only single lesions were observed, 
while in one of the cases (5.6%), lesions were detected 
both in the maxillary bone and in the mandible. In only 
one of the cases, an area of significant mandibular invol-
vement, with an extraoral fistula, was found; the subject 
was a female patient who had received alendronate con-
tinuously for a period of 10 years. (Figs 3,4)
Fig. 1. Areas of exposed necrotic bone.
Fig. 2. Areas of exposed necrotic bone.
Discussion
BPMO has frequently been associated with the use of 
intravenous biphosphonates in patients undergoing 
treatment for hypercalcemia of malignancy or cancer 
with bone metastases; its incidence being very low for 
oral biphosphonates. Over the last few years, the increa-
se in the use of oral biphosphonates for the treatment 
and prophylaxis of osteoporosis has led to an increase 
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Fig. 3. Mandibular involvement with extraoral fistula.
Fig. 4. Mandibular involvement with extraoral fistula.
in the number of described cases of BPMO associated 
to the oral use of these drugs. This is a very disturbing 
fact, since the population suffering from osteoporosis in-
creases every year, and it can be expected the amount of 
patients developing BPMO within this group to rapidly 
rise. Junquera et al. (3) noticed an increase in BPMO 
cases in patients with certain pathologies like rheuma-
toid arthritis, in which the development of serious os-
teoporosis had required treatment with oral biphospho-
nates. This was also observed in all of our patients. In 
a systematic review of 368 cases of BPMO, Woo et al. 
(1) observed that the oral biphosphonate which more 
frequently caused BPMO was alendronate, as we also 
noted in our own review. Lazarovici et al. (2) studied 
27 patients presenting with BPMO, concluding that the 
median time of emergence of the disease was 60 months 
for patients who had taken alendronate, 13 months for 
those who had taken zolendronic acid, and 35 months 
for those who had taken pamidronate. A review of 20 
cases of BPMO conducted by Bagán et al. (11) showed 
an average of 27.3 months for intravenous biphosphona-
tes. In a study of 44 cases, Bocanegra et al. (12) deter-
mined that the average time of appearance of BPMO in 
patients who took alendronate was 7 years. In our study, 
the mean time of onset was 49.32 months for the total of 
patients studied, who took alendronate, ibandronate, or 
a combination of both. Bagán et al. (13) informed of a 
group of 10 patients who presented with posterior man-
dibular osteonecrosis after receiving chemotherapy for 
the treatment of cancer. In 50% of the cases, the osteone-
crosis was located in the mandible, and in most of the ca-
ses the lesion appeared after previous tooth extractions. 
Marín et al. (14) published a series of 5 cases of BPMO 
associated to the intake of oral biphosphonates, with a 
collective history of dental manipulation at the time of 
the diagnosis of BPMO. In our series, over 18 cases re-
viewed, 10 patients presented with lesions in the man-
dible; in 5 of these patients the lesions were preceded 
by dental extractions, in 2 cases by prosthetic-related 
trauma, and in 1 case by dental implants. Ruggiero et al. 
(10) mention 7 cases of BPMO related to osteoporosis 
from a total of 63 patients studied who had BPMO, none 
of which had a history of malignant lesions or previous 
chemotherapy. We present 18 cases of BPMO in patients 
undergoing therapy with oral alendronate or ibandrona-
te, for the treatment of osteopenia or osteoporosis, with 
no history of malignancy or chemotherapy. Bocanegra et 
al. (15) reported 3 cases of BPMO in diabetic female pa-
tients who took oral alendronate, and were submitted to 
dental extractions without proper antibiotic prophylaxis. 
Diabetic patients were excluded from our study. In 2012, 
Diniz et al. (16) informed of 20 cases of BPMO in 19 
female and 1 male patients who took oral biphosphona-
tes (alendronate or ibandronate) with certain similarities 
with our cases. Today, a great number of patients take 
oral biphosphonates worldwide. In Argentina, we obser-
ve a marked increment of BPMO in patients who take 
oral biphosphonates for the prophylaxis or treatment 
of osteoporosis. When these people need dental care, 
we should consider the possibility of them developing 
BPMO, especially when they require dental treatment 
which includes minor surgery (dental extractions, gingi-
vectomy, biopsy or dental implants). Likely prescribers 
of oral biphosphonates (hematologists, traumatologists, 
rheumatologists, gynecologists, oncologists, etc.) should 
assess the possibility of appearance of this adverse effect 
at the time of choosing what to prescribe. In case the-
re was no alternative, the patient should be informed of 
the risk of developing BPMO, and of the importance 
of taking care of their oral health with regard to their 
treatment. The present study does not state any conflict 
of interests.   
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